The guidelines battle on starting statins

New England Journal of Medicine

Volumn 370, Issue 17, 2014, Pages 1652-1658

  Ansell, Benjamin J ^a   Mora, Samia ^b,c   Krumholz, Harlan M ^d,e,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e YALE UNIVERSITY   (United States)

^f YALE NEW HAVEN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; DECISION MAKING; DIABETES MELLITUS; DIABETIC RETINOPATHY; DRUG MONITORING; EVIDENCE BASED PRACTICE; HUMAN; INCIDENCE; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RISK REDUCTION; SMOKING; SMOKING CESSATION; ARTICLE; BLOOD; CASE REPORT; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PATIENT PARTICIPATION; RISK ASSESSMENT; RISK FACTOR;

CHOLESTEROL, LDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PATIENT PARTICIPATION; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS;

EID: 84899112346     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMclde1314766     Document Type: Article

References (15)

1. Kannel WB, Higgins M. Smoking and hypertension as predictors of cardiovascular risk in population studies. J Hypertens Suppl 1990;8:S3-S8.
2. Quitting smoking among adults - United States, 2001-2010. MMWR Morb Mortal Wkly Rep 2011;60:1513-9.
3. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012;380:565-71.
4. Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50. (Pubitemid 32378388)
5. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22. (Pubitemid 28248586)
6. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-65. (Pubitemid 32568149)
7. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-5.
8. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013 November 12 (Epub ahead of print).
9. FDA drug safety communication: important safety label changes to cholesterol-lowering statin drugs. Silver Spring, MD: Food and Drug Administration, 2012 (http://www.fda.gov/drugs/drugsafety/ucm293101.htm).
10. Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA study): a prospective randomised controlled trial. Lancet 2006;368:1155-63. (Pubitemid 44444932)
11. Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 2012;307:1302-9. [Errata, JAMA 2012;307:1694, 1915.]
12. Ting HH, Brito JP, Montori VM. Shared decision making: science and action. Circ Cardiovasc Qual Outcomes 2014 February 4 (Epub ahead of print).
13. Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581-90.
14. Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. Lancet 2013;382:1762-5.
15. Hayward RA, Krumholz HM. Three reasons to abandon low-density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institutes of Health. Circ Cardiovasc Qual Outcomes 2012;5:2-5.